Among patients with heart failure (HF), those taking dapaglifozin or empaglifozin had a 30% odds reduction in HF hospitalization, 14% odds reduction in cardiovascular mortality, and a 10% odds reduction in all-cause mortality compared with patients taking placebo.
Sleep apnea prevalence in cardiology patients was similar to the rates in patients with heart failure., and sleep apnea prevalence in cardio-oncology patients was the same or greater than other traditional risk factors.
Researchers found TET2 clonal hematopoiesis of indeterminate potential (CHIP) to be an independent risk factor associated with incident heart failure with preserved ejection fraction (HFpEF).